Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Born in Algeria, Sebagh obtained a medical degree from the University of Paris and then learned plastic surgery in Los Angeles. For around 15 years, he worked to rebuild cancer victims' faces and heal burns victims' scarring in Paris's Hôpital Foch. In 1997, he divorced his wife, a Parisian dentist. He has a son and a daughter. Sebagh has a line of skin care products called Dr. Sebagh Anti-Aging marketed by Californian-based direct sales company Guthy-Renker and promoted through TV infomercials.
This would reduce the physical bandwidth requirements by 2–3×, placing it well within the capabilities of an HBR2-rated cable. This exemplifies why DisplayPort cables are not classified by "version"; although DSC was introduced in version 1.4, this does not mean it needs a so-called "DP 1.4 cable" (an HBR3-rated cable) to function. HBR3 cables are only required for applications which exceed HBR2-level bandwidth, not simply any application involving DisplayPort 1.4. If DSC is used to reduce the bandwidth requirements to HBR2 levels, then an HBR2-rated cable will be sufficient. In version 2.1, VESA introduced the DP40 and DP80 cable certification tiers, which validate cables for UHBR10 and UHBR20 speeds respectively. DisplayPort 2.1a introduced DP54 cable certification for UHBR13.5 speed.
=== Colloidal suspensions === Without sufficient attraction forces (e.g., Van der Waals force) to aggregate the solid particles together and to remove them from solution by gravity (settling), they remain in suspension and form colloids. Sedimentation can be accelerated by high speed centrifugation. The compact mass thus obtained is sometimes referred to as a 'pellet'.
=== Design and control === Despite the dynamic nature and lack of binding specificity that govern the formation of biomolecular condensates, synthetic condensates can still be engineered to exhibit different behaviors. One popular way to conceptualize condensate interactions and aid in design is through the "sticker-spacer" framework. Multivalent interaction sites, or "stickers", are separated by "spacers", which provide the conformational flexibility and physically separate individual interaction modules from one another. Proteins regions identified as 'stickers' usually consist of Intrinsically Disordered Regions (IDRs) that act as "sticky" biopolymers via short patches of interacting residues patterned along their unstructured chain, which collectively promote LLPS. Another class is RNA-based design demonstrated as TEARS (Transcriptionally Engineered Addressable RNA Solvent droplets), where repeating CAG ribonucleotides (rCAG) function as the multivalent "stickers." to form condensates within bacterial cells. By modifying the sticker-spacer framework, i.e. the polypeptide and RNA sequences as well as their mixture compositions, the material properties (viscous and elastic regimes) of condensates can be tuned to design novel condensates. Other tools outside of tuning the sticker-spacer framework can be used to give new functionality and to allow for high temporal and spatial control over synthetic condensates.
== History == One of the earliest accounts of the tetrahedral intermediate came from Rainer Ludwig Claisen in 1887. In the reaction of benzyl benzoate with sodium methoxide, and methyl benzoate with sodium benzyloxide, he observed a white precipitate which under acidic conditions yields benzyl benzoate, methyl benzoate, methanol, and benzyl alcohol. He named the likely common intermediate “additionelle Verbindung.”
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}&{\text{find }}\mathbf {u} \in L^{2}\left(\mathbb {R} ^{+}\;\left[H^{1}(\Omega )\right]^{d}\right)\cap C^{0}\left(\mathbb {R} ^{+}\;\left[L^{2}(\Omega )\right]^{d}\right){\text{ such that: }}\\[5pt]&\quad {\begin{cases}\displaystyle \int \limits _{\Omega }\rho {\dfrac {\partial \mathbf {u} }{\partial t}}\cdot \mathbf {v} +\int \limits _{\Omega }\mu \nabla \mathbf {u} \cdot \nabla \mathbf {v} +\int \limits _{\Omega }\rho (\mathbf {u} \cdot \nabla )\mathbf {u} \cdot \mathbf {v} -\int \limits _{\Omega }p\nabla \cdot \mathbf {v} =\int \limits _{\Omega }\mathbf {f} \cdot \mathbf {v} +\int \limits _{\Gamma _{N}}\mathbf {h} \cdot \mathbf {v} \quad \forall \mathbf {v} \in V,\\\displaystyle \int \limits _{\Omega }q\nabla \cdot \mathbf {u} =0\quad \forall q\in Q.\end{cases}}\end{aligned}}}
=== Traditional === Rotheca myricoides is used in traditional medicine to manage diabetes in the lower eastern part of Kenya. This area is populated mostly by the Kamba community. They take this medicine daily by boiling and consuming the leaves. This species is also used to treat epilepsy, arthritis, typhoid, cough, eye problems, tonsillitis, rheumatism, gonorrhoea, cancer, malaria, dysmenorrhea, sterility, and impotence. In traditional medicine, European and African cultures used the bark of the species in its powdered form, and a teaspoon is used to treat snakebites. The Masai used the root bark for East Coast fever in cattle and diarrhea in their calves. The Haya and Shambala used Rotheca myricoides for dysmenorrhoea and cough, furunculosis and swellings that are associated with debility. In various African communities, the root of the plant is also used for chest pain, colds, gum bleeding indigestion, headaches, and bathing people with convulsions. In West Africa, the plant is used for analgesic and antipyretic purposes. In Asian countries, this species has been brewed as a tea to relieve swelling and pain.
=== Medications === Medications for PMOS include metformin and oral contraceptives. Metformin is a medication commonly used in type 2 diabetes, and is used frequently off-label in the management of PMOS. It is recommended for those with a BMI over 25 to treat insulin resistance and normalise lipid profiles, and can also be considered for the treatment of irregular periods in adolescents and for those with a BMI under 25. Metformin is associated with several side effects, including abdominal pain, metallic taste in the mouth, diarrhoea and vomiting. It can also be used to help women get pregnant, but it is not the most effective drug for it. Combined oral contraceptives (COCs) can be used to reduce the symptoms of hirsutism and regulate menstrual periods. They increase sex hormone binding globulin production, and reduce levels of androgens. A regular cycle reduces the risk of endometrial cancer. Contraceptive pills with only progestogens can be used to improve menstrual regularity, but not for symptoms of androgen excess. Antiandrogens such as finasteride and flutamide do not show advantages over COCs for treating hirsutism, but can be an option for people for whom COCs are contraindicated or who do not tolerate them. It may take six to twelve months for COCs to be effective for hirsutism. For the treatment of androgenic alopecia, a combination of antiandrogens and combined oral contraceptives can be tried, but it is difficult to treat. GLP-1 receptor agonists, such as liraglutide and semaglutide, may be more effective than metformin alone at metabolic improvements.
== See also == Argo Tea, Chicago based chain of tea cafés Bigelow Tea Company, founded in 1945 in Connecticut with a tea blended with orange and spices, family owned Celestial Seasonings, a pioneering American herbal tea company founded in Colorado, 1969 English breakfast tea, named by an English-American tea merchant in 1843 in New York City The Great Atlantic & Pacific Tea Company, began in 1859 as a tea and coffee dealer in New York; also known as the giant supermarket chain "A&P" List of tea companies#United States Luzianne, a Louisiana-based tea company that introduced an iced tea blend in 1932 Lynchburg lemonade, a cocktail and long drink Salada tea, a tea company founded in Montreal, that built a headquarters in Boston in 1917 Snapple, an American brand of tea and juice drinks which is owned by Dr Pepper Snapple Group and based in Plano, Texas Tea production in the United States Teahouse
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.